Biopharmaceutical company Zai Lab Limited (Nasdaq: ZLAB)(HKEX: 9688) and oncology company Novocure (Nasdaq: NVCR) announced on Monday that the Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) for patients with unresectable, locally advanced pancreatic adenocarcinoma.
Patients treated with Tumor Treating Fields (TTFields) therapy alongside gemcitabine and nab-paclitaxel achieved an mOS of 16.20 months compared to 14.16 months for the control group, a 2.0-month improvement (hazard ratio=0.819; P=0.039) among 571 participants. TTFields therapy also demonstrated increasing survival benefits over time, with 13% and 33% higher survival rates at 12 and 24 months, respectively. Safety results were consistent with prior studies, confirming the therapy's tolerability.
Novocure intends to pursue regulatory approval in the US, EU, Japan and other markets based on these results, while Zai Lab plans filings in China. Pancreatic cancer remains among the deadliest cancers, with a five-year survival rate of 7.2% in China.
TTFields therapy leverages electric fields to disrupt cancer cell division while sparing healthy cells. Already approved for multiple solid tumour types, it has demonstrated enhanced efficacy when combined with existing cancer treatments.
Zai Lab and Novocure aim to expand access to this innovative therapy to address the critical unmet need for effective pancreatic cancer treatments globally.
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Eli Lilly and Co receives approval from FDA for Zepbound
YolTech Therapeutics updates data from Phase I/IIa clinical trial of YOLT-201
AstraZeneca's Tagrisso gains EU approval for advanced lung cancer treatment
Novo Nordisk's CagriSema shows superior weight loss in obesity trial
GSK's Jemperli-Zejula combination shows promise in ovarian cancer
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
BioArctic licenses PyroGlu-Aβ antibody programme to Bristol Myers Squibb
Thor Medical signs supply deal with AdvanCell
MOBILion Systems collaborates with Dr Oliver Schmitz to enhance metabolomics analysis
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial